Vera Therapeutics (VERA) Depreciation & Amortization (CF) (2023 - 2026)

Vera Therapeutics (VERA) has 4 years of Depreciation & Amortization (CF) data on file, last reported at $140000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 64.71% year-over-year to $140000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $523000.0 (up 192.18% YoY) and the FY2025 annual result came in at $468000.0, up 345.71% from the prior year.
• Depreciation & Amortization (CF) rose to $140000.0 in Q1 2026, from $135000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $140000.0 in Q1 2026 to a low of $4000.0 in Q4 2023.
• A 4-year average of $65727.3 and a median of $55000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) jumped 1275.0% — and 2026, when it surged 64.71%.
• Tracing VERA's Depreciation & Amortization (CF) over 4 years: stood at $4000.0 in 2023, then jumped by 1275.0% to $55000.0 in 2024, then soared by 145.45% to $135000.0 in 2025, then advanced by 3.7% to $140000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $140000.0 (Q1 2026), $135000.0 (Q4 2025), and $129000.0 (Q3 2025), per Business Quant data.